EDIT - CIK 0001650664
Editas Medicine, Inc. (EDIT) reported net income of -$160.06M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$160.06M | +32.5% |
| FY 2024 | -$237.09M | -54.7% |
| FY 2023 | -$153.22M | +30.5% |
| FY 2022 | -$220.43M | -14.5% |
| FY 2021 | -$192.50M | -66.0% |
| FY 2020 | -$115.98M | +13.3% |
| FY 2019 | -$133.75M | -21.6% |
| FY 2018 | -$109.95M | +8.6% |
| FY 2017 |
Editas Medicine, Inc. (EDIT) reported net income of -$160.06M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Editas Medicine, Inc.'s net income declined from -$13.69M to -$160.06M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$120.32M |
| -23.8% |
| FY 2016 | -$97.18M | -33.3% |
| FY 2015 | -$72.90M | -432.7% |
| FY 2014 | -$13.69M | - |